Dianthus reports Phase 3 CIDP interim data and gMG trial start, $1.2 billion cash

Dianthus Therapeutics reported second-quarter 2026 results on August 4, 2026, alongside a set of pipeline updates for its lead candidate claseprubart and two earlier-stage programs.

The company said its Phase 3 EMERGE registrational trial of claseprubart in generalized Myasthenia Gravis, testing 300mg/2mL doses every two or four weeks subcutaneously, started in June, with top-line results expected in the second half of 2028.¹

In Chronic Inflammatory Demyelinating Polyneuropathy, an interim analysis of the first 40 participants who completed Part A of the Phase 3 CAPTIVATE trial showed a 75% response rate, above the trial's target response rate of 50% or more, which the company said was set based on prior experience with anti-C1s inhibition.¹ The company said results were consistent across multiple efficacy measures, and claseprubart showed no related serious infections, no clinical signs of drug-induced lupus, and no related serious adverse events or discontinuations for safety.¹ Dianthus expects to give Part B top-line guidance for CAPTIVATE by the end of 2026.¹

In Multifocal Motor Neuropathy, the Phase 2 MoMeNtum trial exceeded its original enrollment target of 36 patients, with top-line results from 46 patients on track for December 2026.¹

For its rheumatology candidate DNTH212, a two-part Phase 1 study in China covering healthy volunteers and lupus patients started in December 2025, with healthy-volunteer data expected by year end 2026.¹

The company also introduced DNTH312, described as a fusion protein it developed internally that combines claseprubart with TACI, aimed at inhibiting both the classical complement pathway and BAFF/APRIL signaling¹, which it aims to have ready for Phase 1 testing by the end of 2027.¹

On finances, Dianthus reported roughly $1.2 billion in cash, cash equivalents and investments as of June 30, 2026, which it said should fund operations into 2030.¹